Hanlin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hanlin Wang has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Jia Li
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
10 shared publications Weijuan Kan
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
5 shared publications- Yi Zang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4 shared publications Bixi Tang
Lingang Laboratory, Shanghai, China
2 shared publicationsBo Wang
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2 shared publicationsCong Li
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8934
Bariatric surgery resolves MASH by enhancing MAT1A-dependent one-carbon metabolism
Bariatric surgery shows variable efficacy in resolving metabolic dysfunction-associated steatohepatitis (MASH), with mechanisms underlying therapeutic heterogeneity remaining unclear. Using multiple male murine MASH models, we demonstrate that vertical sleeve gastrectomy (VSG) ameliorates hepatic steatosis and fibrosis through mechanisms that extend beyond weight loss. Multi-omic profiling reveals VSG enhances hepatic one-carbon metabolism (1CM) via upregulation of methionine adenosyltransferase 1 A (MAT1A), increasing S-adenosylmethionine (SAM) availability and the SAM/SAH ratio. This metabolic reprogramming restores hepatic phosphatidylcholine (PC) /phosphatidylethanolamine (PE) homeostasis, alleviating endoplasmic reticulum stress and mitochondrial dysfunction. Critically, dietary depletion of one-carbon substrates or genetic ablation of MAT1A abolishes VSG’s therapeutic effects, while betaine supplementation rescues surgical efficacy. In humans, paired liver biopsies from patients with MASH (n = 4) show MAT1A upregulation correlating with histological improvement, while plasma metabolomics from a separate cohort (n = 42) reveals that patients with poor hepatic response to VSG display compromised one-carbon metabolism signatures, with SAM levels correlating with therapeutic response. These findings establish MAT1A-mediated methylation as an essential mechanism for optimal VSG efficacy in preclinical models and identify one-carbon metabolites as candidate biomarkers for predicting surgical response, suggesting that preoperative metabolic profiling could guide methyl donor supplementation to optimize VSG outcomes in MASH.
- 22 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8934
Open AccessBariatric surgery resolves MASH by enhancing MAT1A-dependent one-carbon metabolism
Bariatric surgery shows variable efficacy in resolving metabolic dysfunction-associated steatohepatitis (MASH), with mechanisms underlying therapeutic heterogeneity remaining unclear. Using multiple male murine MASH models, we demonstrate that vertical sleeve gastrectomy (VSG) ameliorates hepatic steatosis and fibrosis through mechanisms that extend beyond weight loss. Multi-omic profiling reveals VSG enhances hepatic one-carbon metabolism (1CM) via upregulation of methionine adenosyltransferase 1 A (MAT1A), increasing S-adenosylmethionine (SAM) availability and the SAM/SAH ratio. This metabolic reprogramming restores hepatic phosphatidylcholine (PC) /phosphatidylethanolamine (PE) homeostasis, alleviating endoplasmic reticulum stress and mitochondrial dysfunction. Critically, dietary depletion of one-carbon substrates or genetic ablation of MAT1A abolishes VSG’s therapeutic effects, while betaine supplementation rescues surgical efficacy. In humans, paired liver biopsies from patients with MASH (n = 4) show MAT1A upregulation correlating with histological improvement, while plasma metabolomics from a separate cohort (n = 42) reveals that patients with poor hepatic response to VSG display compromised one-carbon metabolism signatures, with SAM levels correlating with therapeutic response. These findings establish MAT1A-mediated methylation as an essential mechanism for optimal VSG efficacy in preclinical models and identify one-carbon metabolites as candidate biomarkers for predicting surgical response, suggesting that preoperative metabolic profiling could guide methyl donor supplementation to optimize VSG outcomes in MASH.
- Top Cited Papers
- 10 June 2026
- Published by Springer Nature in Nature
- Vol. 655 (8123) , 1-11
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor activation that mirrors endogenous bile acid dynamics3,4,5. Linafexor has robust efficacy across multiple preclinical models of metabolic dysfunction-associated steatohepatitis6, liver fibrosis7, primary biliary cholangitis and primary sclerosing cholangitis8,9. Transcriptomic analyses reveal that, unlike long-acting FXR agonists10,11, linafexor preserves cyclic FXR signalling, avoids receptor downregulation and prevents broad transcriptional dysregulation. Direct manipulation of delivery patterns demonstrates that sustained FXR activation—independent of compound identity—induces severe toxicity, establishing activation duration as a determinant of therapeutic index. In phase 1 clinical studies (ClinicalTrials.gov; NCT05082779), linafexor administered once daily produces transient FXR pathway engagement, marked by (1) induction of FGF1912,13,14, a key endocrine mediator of bile acid feedback regulation; and (2) suppression of C415, an intermediate reflecting hepatic bile acid synthesis, with no treatment-related adverse events. Together, these findings identify pulsatile FXR activation as a mechanistically grounded and clinically translatable strategy, and establish linafexor as a first-in-class therapeutic for bile acid–related liver diseases.
- 10 June 2026
- Published by Springer Nature in Nature
- Vol. 655 (8123) , 1-11
Top Cited PapersA first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor activation that mirrors endogenous bile acid dynamics3,4,5. Linafexor has robust efficacy across multiple preclinical models of metabolic dysfunction-associated steatohepatitis6, liver fibrosis7, primary biliary cholangitis and primary sclerosing cholangitis8,9. Transcriptomic analyses reveal that, unlike long-acting FXR agonists10,11, linafexor preserves cyclic FXR signalling, avoids receptor downregulation and prevents broad transcriptional dysregulation. Direct manipulation of delivery patterns demonstrates that sustained FXR activation—independent of compound identity—induces severe toxicity, establishing activation duration as a determinant of therapeutic index. In phase 1 clinical studies (ClinicalTrials.gov; NCT05082779), linafexor administered once daily produces transient FXR pathway engagement, marked by (1) induction of FGF1912,13,14, a key endocrine mediator of bile acid feedback regulation; and (2) suppression of C415, an intermediate reflecting hepatic bile acid synthesis, with no treatment-related adverse events. Together, these findings identify pulsatile FXR activation as a mechanistically grounded and clinically translatable strategy, and establish linafexor as a first-in-class therapeutic for bile acid–related liver diseases.
- Open Access
- 23 March 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 108
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation
Epigenetic dysregulation is a fundamental cancer hallmark, and lysine demethylase 1 (LSD1) is a central target for cancer intervention. Developing novel LSD1 inhibitors with high selectivity, favorable bioavailability, and safety for acute myeloid leukemia (AML) remains challenging. We developed DC551040, a highly potent, selective irreversible LSD1 inhibitor with good tolerability in Phase I AML clinical trial (CTR20222026). DC551040-LSD1 complex crystal structure uncovered a new binding pocket, providing molecular insights for subsequent LSD1 inhibitor design. Given the significant role of LSD1 in epigenetic regulation, we performed comprehensive transcriptomic and proteomic analyses to investigate gene and protein expression dynamics following DC551040 treatment in an MV-4-11 xenograft model. These analyses revealed that multiple immune and inflammation related pathways are activated upon DC551040 treatment, including the key members STAT5, NF-κB, and AKT, suggesting the potential for adaptive resistance. Through a search of the Connectivity Map (CMAP) database, we identify homoharringtonine (HHT), an approved anti-leukemia drug, which mimics the anti-transcriptional activation of inflammatory pathways. Subsequent in vitro and in vivo experiments validated the efficacy of combining HHT with DC551040, demonstrating a synergistic antitumor effect and extended survival in MV-4-11 disseminated xenograft model mice. Together, this study not only introduces a novel LSD1 inhibitor but also delves into the molecular mechanisms underlying LSD1 inhibitors, while proposing a promising combination therapy for AML individuals in clinical trials.
- 23 March 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 108
Open AccessPotent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation
Epigenetic dysregulation is a fundamental cancer hallmark, and lysine demethylase 1 (LSD1) is a central target for cancer intervention. Developing novel LSD1 inhibitors with high selectivity, favorable bioavailability, and safety for acute myeloid leukemia (AML) remains challenging. We developed DC551040, a highly potent, selective irreversible LSD1 inhibitor with good tolerability in Phase I AML clinical trial (CTR20222026). DC551040-LSD1 complex crystal structure uncovered a new binding pocket, providing molecular insights for subsequent LSD1 inhibitor design. Given the significant role of LSD1 in epigenetic regulation, we performed comprehensive transcriptomic and proteomic analyses to investigate gene and protein expression dynamics following DC551040 treatment in an MV-4-11 xenograft model. These analyses revealed that multiple immune and inflammation related pathways are activated upon DC551040 treatment, including the key members STAT5, NF-κB, and AKT, suggesting the potential for adaptive resistance. Through a search of the Connectivity Map (CMAP) database, we identify homoharringtonine (HHT), an approved anti-leukemia drug, which mimics the anti-transcriptional activation of inflammatory pathways. Subsequent in vitro and in vivo experiments validated the efficacy of combining HHT with DC551040, demonstrating a synergistic antitumor effect and extended survival in MV-4-11 disseminated xenograft model mice. Together, this study not only introduces a novel LSD1 inhibitor but also delves into the molecular mechanisms underlying LSD1 inhibitors, while proposing a promising combination therapy for AML individuals in clinical trials.
- 5 February 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118641
Discovery and optimization of Menin-MLL inhibitors targeting acute myeloid leukemia
- 5 February 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118641
Discovery and optimization of Menin-MLL inhibitors targeting acute myeloid leukemia
- 13 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 800, 153284
Ferroptosis regulation and acute leukemia: Mechanisms and therapeutic perspectives
- 13 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 800, 153284
Ferroptosis regulation and acute leukemia: Mechanisms and therapeutic perspectives
- Open Access
- 17 April 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (6)
ZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13
Peroxisomes are integral metabolic organelles involved in both catabolic and anabolic processes in humans, with defects linked to diseases. The functions of peroxisomes are regulated at transcriptional, translational, and posttranslational levels. In this study, we employed the CRISPR/Cas9-based screening of a ubiquitin ligase library to identify regulators of human peroxisomes. We discovered that ZBTB17 (MIZ1) plays a role in regulating the import of proteins into peroxisomes. Independent of its ubiquitin ligase activity, ZBTB17/MIZ1 operates as a transcription factor to modulate the expression of key importer PEX13, influencing the localization of peroxisomal enzymes. Furthermore, metabolomic profiling reveals that knockdown of ZBTB17 or PEX13 results in similar metabolic alterations, with downregulated purine synthesis. Collectively, we identify ZBTB17 as a key regulator of peroxisomal protein import, thereby affecting peroxisomal function and nucleotide metabolism. Our findings provide insights into the multifaceted regulation of peroxisomes in complex human cells and shed light on the molecular mechanisms underlying ZBTB17’s role as a transcriptional regulator.
- 17 April 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (6)
Open AccessZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13
Peroxisomes are integral metabolic organelles involved in both catabolic and anabolic processes in humans, with defects linked to diseases. The functions of peroxisomes are regulated at transcriptional, translational, and posttranslational levels. In this study, we employed the CRISPR/Cas9-based screening of a ubiquitin ligase library to identify regulators of human peroxisomes. We discovered that ZBTB17 (MIZ1) plays a role in regulating the import of proteins into peroxisomes. Independent of its ubiquitin ligase activity, ZBTB17/MIZ1 operates as a transcription factor to modulate the expression of key importer PEX13, influencing the localization of peroxisomal enzymes. Furthermore, metabolomic profiling reveals that knockdown of ZBTB17 or PEX13 results in similar metabolic alterations, with downregulated purine synthesis. Collectively, we identify ZBTB17 as a key regulator of peroxisomal protein import, thereby affecting peroxisomal function and nucleotide metabolism. Our findings provide insights into the multifaceted regulation of peroxisomes in complex human cells and shed light on the molecular mechanisms underlying ZBTB17’s role as a transcriptional regulator.
- Open Access
- 18 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Macrophage SUCLA2 coupled glutaminolysis manipulates obesity through AMPK
Obesity is regarded as a chronic inflammatory disease involving adipose tissue macrophages (ATM), but whether immunometabolic reprogramming of ATM affects obesity remains unclarified. Here we show that in ATM glutaminolysis is the fundamental metabolic flux providing energy and substrate, bridging with AMP-activated protein kinase (AMPK) activity, succinate-induced interleukin-1β (IL-1β) production, and obesity. Abrogation of AMPKα in myeloid cells promotes proinflammatory ATM, impairs thermogenesis and energy expenditure, and aggravates obesity in mice fed with high-fat diet (HFD). Conversely, IL-1β neutralization or myeloid IL-1β abrogation prevents obesity caused by AMPKα deficiency. Mechanistically, ATP generated from glutaminolysis suppresses AMPK to decrease phosphorylation of the β subunit of succinyl-CoA synthetase (SUCLA2), thereby resulting in the activation of succinyl-CoA synthetase and the overproduction of succinate and IL-1β; by contrast, siRNA-mediated SUCLA2 knockdown reduces obesity induced by HFD in mice. Lastly, phosphorylated SUCLA2 in ATM correlates negatively with obesity in humans. Our results thus implicate a glutaminolysis/AMPK/SUCLA2/IL-1β axis of inflammation and obesity regulation in ATM.
- 18 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessMacrophage SUCLA2 coupled glutaminolysis manipulates obesity through AMPK
Obesity is regarded as a chronic inflammatory disease involving adipose tissue macrophages (ATM), but whether immunometabolic reprogramming of ATM affects obesity remains unclarified. Here we show that in ATM glutaminolysis is the fundamental metabolic flux providing energy and substrate, bridging with AMP-activated protein kinase (AMPK) activity, succinate-induced interleukin-1β (IL-1β) production, and obesity. Abrogation of AMPKα in myeloid cells promotes proinflammatory ATM, impairs thermogenesis and energy expenditure, and aggravates obesity in mice fed with high-fat diet (HFD). Conversely, IL-1β neutralization or myeloid IL-1β abrogation prevents obesity caused by AMPKα deficiency. Mechanistically, ATP generated from glutaminolysis suppresses AMPK to decrease phosphorylation of the β subunit of succinyl-CoA synthetase (SUCLA2), thereby resulting in the activation of succinyl-CoA synthetase and the overproduction of succinate and IL-1β; by contrast, siRNA-mediated SUCLA2 knockdown reduces obesity induced by HFD in mice. Lastly, phosphorylated SUCLA2 in ATM correlates negatively with obesity in humans. Our results thus implicate a glutaminolysis/AMPK/SUCLA2/IL-1β axis of inflammation and obesity regulation in ATM.
- 20 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (3) , 605-617
Hepatic glucuronyl C5-epimerase combats obesity by stabilising GDF15
- 20 May 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (3) , 605-617
Hepatic glucuronyl C5-epimerase combats obesity by stabilising GDF15
- Open Access
- 5 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
The outcomes of FLT3-ITD acute myeloid leukaemia (AML) have been improved since the approval of FLT3 inhibitors (FLT3i). However, approximately 30-50% of patients exhibit primary resistance (PR) to FLT3i with poorly defined mechanisms, posing a pressing clinical unmet need. Here, we identify C/EBPα activation as a top PR feature by analyzing data from primary AML patient samples in Vizome. C/EBPα activation limit FLT3i efficacy, while its inactivation synergistically enhances FLT3i action in cellular and female animal models. We then perform an in silico screen and identify that guanfacine, an antihypertensive medication, mimics C/EBPα inactivation. Furthermore, guanfacine exerts a synergistic effect with FLT3i in vitro and in vivo. Finally, we ascertain the role of C/EBPα activation in PR in an independent cohort of FLT3-ITD patients. These findings highlight C/EBPα activation as a targetable PR mechanism and support clinical studies aimed at testing the combination of guanfacine with FLT3i in overcoming PR and enhancing the efficacy of FLT3i therapy.
- 5 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessTargeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
The outcomes of FLT3-ITD acute myeloid leukaemia (AML) have been improved since the approval of FLT3 inhibitors (FLT3i). However, approximately 30-50% of patients exhibit primary resistance (PR) to FLT3i with poorly defined mechanisms, posing a pressing clinical unmet need. Here, we identify C/EBPα activation as a top PR feature by analyzing data from primary AML patient samples in Vizome. C/EBPα activation limit FLT3i efficacy, while its inactivation synergistically enhances FLT3i action in cellular and female animal models. We then perform an in silico screen and identify that guanfacine, an antihypertensive medication, mimics C/EBPα inactivation. Furthermore, guanfacine exerts a synergistic effect with FLT3i in vitro and in vivo. Finally, we ascertain the role of C/EBPα activation in PR in an independent cohort of FLT3-ITD patients. These findings highlight C/EBPα activation as a targetable PR mechanism and support clinical studies aimed at testing the combination of guanfacine with FLT3i in overcoming PR and enhancing the efficacy of FLT3i therapy.
- Open Access
- 6 March 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-17
Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis
Epithelial to mesenchymal transition (EMT) plays a crucial role in cancer metastasis, accompanied with vast epigenetic changes. AMP-activated protein kinase (AMPK), a cellular energy sensor, plays regulatory roles in multiple biological processes. Although a few studies have shed light on AMPK regulating cancer metastasis, the inside epigenetic mechanisms remain unknown. Herein we show that AMPK activation by metformin relieves the repressive H3K9me2-mediated silencing of epithelial genes (e.g., CDH1) during EMT processes and inhibits lung cancer metastasis. PHF2, a H3K9me2 demethylase, was identified to interact with AMPKα2. Genetic deletion of PHF2 aggravates lung cancer metastasis and abolishes the H3K9me2 downregulation and anti-metastasis effect of metformin. Mechanistically, AMPK phosphorylates PHF2 at S655 site, enhancing PHF2 demethylation activity and triggering the transcription of CDH1. Furthermore, the PHF2-S655E mutant that mimics AMPK-mediated phosphorylation status further reduces H3K9me2 and suppresses lung cancer metastasis, while PHF2-S655A mutant presents opposite phenotype and reverses the anti-metastasis effect of metformin. PHF2-S655 phosphorylation strikingly reduces in lung cancer patients and the higher phosphorylation level predicts better survival. Altogether, we reveal the mechanism of AMPK inhibiting lung cancer metastasis via PHF2 mediated H3K9me2 demethylation, thereby promoting the clinical application of metformin and highlighting PHF2 as the potential epigenetic target in cancer metastasis.
- 6 March 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-17
Open AccessPhosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis
Epithelial to mesenchymal transition (EMT) plays a crucial role in cancer metastasis, accompanied with vast epigenetic changes. AMP-activated protein kinase (AMPK), a cellular energy sensor, plays regulatory roles in multiple biological processes. Although a few studies have shed light on AMPK regulating cancer metastasis, the inside epigenetic mechanisms remain unknown. Herein we show that AMPK activation by metformin relieves the repressive H3K9me2-mediated silencing of epithelial genes (e.g., CDH1) during EMT processes and inhibits lung cancer metastasis. PHF2, a H3K9me2 demethylase, was identified to interact with AMPKα2. Genetic deletion of PHF2 aggravates lung cancer metastasis and abolishes the H3K9me2 downregulation and anti-metastasis effect of metformin. Mechanistically, AMPK phosphorylates PHF2 at S655 site, enhancing PHF2 demethylation activity and triggering the transcription of CDH1. Furthermore, the PHF2-S655E mutant that mimics AMPK-mediated phosphorylation status further reduces H3K9me2 and suppresses lung cancer metastasis, while PHF2-S655A mutant presents opposite phenotype and reverses the anti-metastasis effect of metformin. PHF2-S655 phosphorylation strikingly reduces in lung cancer patients and the higher phosphorylation level predicts better survival. Altogether, we reveal the mechanism of AMPK inhibiting lung cancer metastasis via PHF2 mediated H3K9me2 demethylation, thereby promoting the clinical application of metformin and highlighting PHF2 as the potential epigenetic target in cancer metastasis.